Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AMPH 
Amphastar P (AMPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: AMPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32
1 Year Target Price $32
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.33% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio 11.85 | 1Y Target Price 32 |
Price to earnings Ratio 11.85 | 1Y Target Price 32 | ||
Volume (30-day avg) 6 | Beta 0.91 | 52 Weeks Range 20.39 - 45.39 | Updated Date 12/8/2025 |
52 Weeks Range 20.39 - 45.39 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-10 | When - | Estimate 0.8523 | Actual 0.93 |
Profitability
Profit Margin 15.43% | Operating Margin (TTM) 25.24% |
Management Effectiveness
Return on Assets (TTM) 6.74% | Return on Equity (TTM) 14.84% |
Valuation
Trailing PE 11.85 | Forward PE - | Enterprise Value 1610703697 | Price to Sales(TTM) 1.72 |
Enterprise Value 1610703697 | Price to Sales(TTM) 1.72 | ||
Enterprise Value to Revenue 2.23 | Enterprise Value to EBITDA 7.23 | Shares Outstanding 45952174 | Shares Floating 34681944 |
Shares Outstanding 45952174 | Shares Floating 34681944 | ||
Percent Insiders 24.3 | Percent Institutions 73.91 |
Upturn AI SWOT
Amphastar P
Company Overview
History and Background
Amphastar Pharmaceuticals, Inc. (Amphastar P) was founded in 1996. It is a vertically integrated specialty pharmaceutical company. Key milestones include the development and FDA approval of complex injectable and inhalation products. The company has evolved to focus on generics and branded products in various therapeutic areas.
Core Business Areas
- Injectable Products: Development, manufacturing, and marketing of generic and proprietary injectable pharmaceutical products. This includes products for critical care, anesthesia, and anti-infectives.
- Inhalation Products: Focuses on developing and commercializing generic and proprietary inhalation products, particularly for respiratory conditions.
- API Manufacturing: Amphastar operates its own Active Pharmaceutical Ingredient (API) manufacturing facilities, providing a competitive advantage in controlling supply and cost for its finished products.
Leadership and Structure
Amphastar Pharmaceuticals is led by a seasoned management team with extensive experience in the pharmaceutical industry. The organizational structure is designed to support its vertically integrated business model, encompassing R&D, manufacturing, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Product Name 1: Aminocaproic Acid (Generic Injectable) - A generic injectable used to control or prevent excessive bleeding. Competitors include other generic injectable manufacturers. Specific market share data is proprietary but it is a significant product.
- Product Name 2: Naloxone Hydrochloride Injection (Generic Injectable) - Used to reverse opioid overdose. Competitors include other generic injectable manufacturers and companies with branded naloxone products. Amphastar has a strong presence in this market.
- Product Name 3: Enoxaparin Sodium Injection (Generic Injectable) - A low molecular weight heparin used as an anticoagulant. Competitors include the originator brand (Lovenox) and other generic manufacturers. This is a highly competitive market.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the generics and specialty injectables sector, is characterized by intense competition, stringent regulatory oversight, and evolving pricing pressures. The demand for complex generics and biosimil-like products is growing.
Positioning
Amphastar P is positioned as a manufacturer of complex generic and specialty injectable and inhalation products. Its vertical integration, with in-house API manufacturing, provides a competitive advantage in terms of cost control and supply chain security. The company also holds a portfolio of proprietary products.
Total Addressable Market (TAM)
The TAM for the generic injectable and inhalation markets is substantial and growing, driven by healthcare demand and patent expirations. Amphastar P targets specific niches within these large markets where its expertise in complex manufacturing can be leveraged. Its positioning is focused on a significant portion of these niche markets rather than a broad market share.
Upturn SWOT Analysis
Strengths
- Vertical integration with in-house API manufacturing.
- Expertise in developing and manufacturing complex injectable and inhalation products.
- Established regulatory affairs and quality control systems.
- Portfolio of both generic and proprietary products.
- Experienced management team.
Weaknesses
- Dependence on a few key products.
- Subject to pricing pressures in the generic market.
- Potential for manufacturing disruptions or quality issues.
- Limited geographic diversification compared to larger pharma companies.
Opportunities
- Expansion of product pipeline through R&D and acquisitions.
- Entry into new therapeutic areas and international markets.
- Leveraging its API manufacturing capabilities for contract manufacturing.
- Increasing demand for complex generics and biosimil-like products.
- Potential for strategic partnerships.
Threats
- Intense competition from both generic and branded manufacturers.
- Regulatory changes and increased scrutiny.
- Price erosion and reimbursement challenges.
- Patent challenges and litigation.
- Supply chain disruptions and raw material cost fluctuations.
Competitors and Market Share
Key Competitors
- Teva Pharmaceutical Industries Ltd. (TEVA)
- Viatris Inc. (VTRS)
- Amneal Pharmaceuticals, Inc. (AMRX)
- Hikma Pharmaceuticals PLC (HIK.L)
Competitive Landscape
Amphastar P competes in a highly fragmented market. Its advantages lie in its focus on complex generics and proprietary products, along with its vertical integration. However, it faces intense price competition and the challenges of scale compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Amphastar P has demonstrated historical growth through the successful development and commercialization of its complex generic products, as well as through strategic acquisitions and pipeline expansion. Revenue growth has been influenced by market penetration of its key offerings.
Future Projections: Future growth projections for Amphastar P are typically based on analyst estimates and company guidance, considering the launch of new products, market trends in its therapeutic areas, and the competitive landscape. Growth is expected to be driven by its specialty generics and proprietary products.
Recent Initiatives: Recent strategic initiatives may include new product development, regulatory submissions for upcoming drugs, expansion of manufacturing capacity, and potential strategic partnerships or collaborations to enhance its product pipeline and market reach.
Summary
Amphastar P is a vertically integrated specialty pharmaceutical company focused on complex generics and proprietary products in injectables and inhalation. Its strengths lie in its manufacturing capabilities and product development expertise. However, it faces significant competition and pricing pressures in the generic market. Continued investment in R&D and strategic expansion are crucial for sustained growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- Financial News Outlets
- Industry Analyst Reports
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Market share data is estimated and may vary. Users should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amphastar P
Exchange NASDAQ | Headquaters Rancho Cucamonga, CA, United States | ||
IPO Launch date 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director Dr. Yongfeng Zhang Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2028 | Website https://www.amphastar.com |
Full time employees 2028 | Website https://www.amphastar.com | ||
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.